Teon has assembled a powerhouse leadership team with a track record in oncology drug development and deep insights in G-protein coupled receptor (GPCR) signaling, small molecule design, along with a clear vision to push the boundaries of science in the immuno-oncology market.
Teon’s team is comprised of determined thinkers and doers who have identified bold, disruptive ideas. And we’re committed to developing and delivering important medicines to patients. We boast a strong pedigree with proven success and the know-how and experience to move our robust immuno-oncology pipeline forward. Our highly accomplished leadership team is comprised of experts in tumor metabolism, cell signaling and GPCR therapeutic design.
We are on a relentless mission to push the boundaries of science in cancer care as we know it today. Only 12% of patients with solid tumors are served by immunotherapy drugs available today. We are guided by the goal to ensure no patient with cancer ever hears the words, “there are no more options for you.”
We bring our hearts and souls to this important work. We are guided by our shared experiences of serving patients with cancer, including our own cancer battles, those of our loved ones, and patients we’ve helped and served along the way. This work is deeply personal, vitally important, and potentially lifesaving. Our team of leaders, scientists, advisors, and board members come together day in and day out with a singular purpose to push the boundaries of science in cancer care as we know it today.